AstraZeneca COVID-19 Vaccine Phase 3 Trials Halted After Suspected Adverse Reaction in UK Participant
By HospiMedica International staff writers Posted on 09 Sep 2020 |
Image: AstraZeneca COVID-19 Vaccine Phase 3 Trials Halted After Suspected Adverse Reaction in UK Participant (Photo courtesy of AstraZeneca).
AstraZeneca (Cambridgeshire, England) has halted a large Phase 3 study of its COVID-19 vaccine at dozens of sites across the US has due to a suspected serious adverse reaction in a participant.
AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to STAT News, a number of different reactions can qualify as suspected serious adverse reactions, symptoms that require hospitalization, life-threatening illness and even death. An individual familiar with the matter told STAT News that the nature of the adverse reaction and when it happened were not immediately known, although the participant was expected to recover. It was also not clear in which clinical trial the adverse reaction occurred, although it appears to have taken place in the Phase 2/3 trial underway in the UK.
An AstraZeneca spokesperson told STAT News that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.” The spokesperson termed the pause as “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.” AstraZeneca is “working to expedite the review of the single event to minimize any potential impact on the trial timeline,” according to the spokesperson.
An individual familiar with the development told STAT News that a hold was placed on the trial out of “an abundance of caution.” Another individual familiar with the matter told STAT News that the finding was impacting other AstraZeneca vaccine trials underway, as well as the clinical trials conducted by other vaccine manufacturers.
Related Links:
AstraZeneca
University of Oxford
AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). According to STAT News, a number of different reactions can qualify as suspected serious adverse reactions, symptoms that require hospitalization, life-threatening illness and even death. An individual familiar with the matter told STAT News that the nature of the adverse reaction and when it happened were not immediately known, although the participant was expected to recover. It was also not clear in which clinical trial the adverse reaction occurred, although it appears to have taken place in the Phase 2/3 trial underway in the UK.
An AstraZeneca spokesperson told STAT News that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.” The spokesperson termed the pause as “a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.” AstraZeneca is “working to expedite the review of the single event to minimize any potential impact on the trial timeline,” according to the spokesperson.
An individual familiar with the development told STAT News that a hold was placed on the trial out of “an abundance of caution.” Another individual familiar with the matter told STAT News that the finding was impacting other AstraZeneca vaccine trials underway, as well as the clinical trials conducted by other vaccine manufacturers.
Related Links:
AstraZeneca
University of Oxford
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans